HDAC-IN-67 (compound 27f) is an HDAC inhibitor against HDAC1 and HDAC6, with IC50 values of 22 nM and 8 nM, respectively. HDAC-IN-67 inhibits cell proliferation and induces cell apoptosis. HDAC-IN-67 exhibits antitumor activity[1].
in vivo
HDAC-IN-67 (i.v.:50 mg/kg) reveals a clearance (CL) of 65.1 ml/(h·kg) and a half-life (T1/2) of 0.361 h after i.v.[1].
HDAC-IN-67 (p.o.:10 mg/kg) exhibits low oral bioavailability(F=3.15%)[1].
HDAC-IN-67 (i.p.:50mg/kg once daily for 21 days) demonstrates a moderate in vivo antitumor potency with TGI of 31.5%[1].
Animal Model:
Female ICR mice/antitumour potency[1]
Dosage:
i.p., 50 mg/kg once a day for 21 days
Administration:
Intraperitoneal injection (i.p.)
Result:
Exhibited in vivo antitumorpotency with TGI of 31.5%.
IC 50
HDAC6: 8 nM (IC50); HDAC1: 22 nM (IC50)
References
[1] Gao Y,et al., Design, synthesis and biological evaluation of novel histone deacetylase (HDAC) inhibitors derived from β-elemene scaffold. J Enzyme Inhib Med Chem. 2023 Dec;38(1):2195991. DOI:10.1080/14756366.2023.2195991